Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 switch study from TDF-containing antiretroviral regimen to E/C/F/TAF in virologically suppressed adults with HIV-1
2012-005114-20Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Started Mar 2013; status: completed.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2012-005114-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005114-20.